Yıl: 2019 Cilt: 26 Sayı: 4 Sayfa Aralığı: 646 - 652 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2018.12.279 İndeks Tarihi: 26-12-2019

Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?

Öz:
Aim: During pregnancy, untreated infections may be associated with low birth weight, preterm birth, and spontaneous abortion. Thus, use of antibiotics are commonly seen in pregnancy. In this study, we aimed to evaluate the possible teratogenic risks related to the maternally exposed antibiotics during pregnancy.Material and Methods: Data from pregnant women, who used antibiotics for several infectious diseases between 2014 and 2018, and admitted to our Teratology Information Service for drug analysis, were collected. Data concerning their medication, concomitant drugs and co-morbidities were documented. The possible teratogenic risks related to the drugs were evaluated. A follow-up was conducted with the women after delivery to obtain whether any major or minor congenital malformations occurred in the infants.Results: The maternal use of doxycycline between 3-6th weeks, and acyclovir between 1-2nd weeks of pregnancy resulted in elective termination. The maternal use of cefazoline between 3-4th weeks of pregnancy, and the use of amoxicillin-clavulanate between 3-6th weeks of gestation resulted in spontaneous abortion. In the outcome of one pregnancy, the concomitant exposure of miconazole, metronidazole, ciprofloxacin, ornidazole and isoconazole in the first two weeks of pregnancy resulted in hypothyroidism in the infant.Conclusions: Antibiotics presented no major teratogenic effects. However, their use in pregnancy should be used only when indicated. Pregnant women should have access to the information and specific advice on the use of medications with proven safety in pregnancy through counseling with the Teratology Information Services.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152:1-39.
  • 2. Zomerdijk IM, Ruiter R, Houweling LM, et al. Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study. BJOG 2015;122:1119-29.
  • 3. Dathe K, Schaefer C. Drug safety in pregnancy: the German Embryotox institute. Eur J Clin Pharmacol 2018;74:171-9.
  • 4. Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom (Kyoto) 2011;51:6-11.
  • 5. Loane M, Dolk H, Kelly A, et al. EUROCAT Working Group. Paper 4: EUROCAT statistical monitoring: identification and investigation of ten year trends of congenital anomalies in Europe. Birth Defects Res A Clin Mol Teratol 2011;91:31-43.
  • 6. Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995;28:59-64.
  • 7. Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143:75-8.
  • 8. Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. Antimicrob Agents Chemother 2014;58:4392-8.
  • 9. Nathan L, Bawdon RE, Sidawi JE, et al. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol 1993;82:338-42.
  • 10. 10. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(RR-03):1-137.
  • 11. Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523-5.
  • 12. Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth JAMA. 2016;315:58-67.
  • 13. Daniel S, Rotem R, Koren G, et al. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol 2018;218:601-7.
  • 14. Pasternak B, Wintzell V, Furu K, et al. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. JAMA 2018;319:2333-5.
  • 15. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005;73:919-23.
  • 16. Howley MM, Carter TC, Browne ML, et al; National Birth Defects Prevention Study. Fluconazole use and birth defects in the National Birth Defects Prevention Study. Am J Obstet Gynecol 2016;214:657.e1-9.
  • 17. Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008;62:172-6.
  • 18. Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013;369:830-9.
  • 19. nman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy.Eur J Clin Pharmacol 1994;46:115-8.
  • 20. Stevens RE, Konsil J, Verrill SS, et al. Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol 2002;42:52-60.
  • 21. Xiong X, Buekens P, Fraser WD, et al. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG 2006;113:135-43.
  • 22. Vergnes JN, Sixou M. Preterm low birth weight and maternal periodontal status: a meta-analysis. Am J Obstet Gynecol 2007;196:135.e1-7.
  • 23. Boggess KA, Moss K, Madianos P, et al. Fetal immune response to oral pathogens and risk of preterm birth. Am J Obstet Gynecol 2005;193:1121-6.
  • 24. Nakhai-Pour HR, Broy P, Sheehy O, et al. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011;183:1713-20.
  • 25. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2015;8:CD000490.
  • 26. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009;163:978-85.
  • 27. Andersen JT, Petersen M, Jimenez-Solem E, et al. Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study. Epidemiol Infect 2013;141:1749-55.
  • 28. Le J, Briggs GG, McKeown A, et al. Urinary tract infections during pregnancy. Ann Pharmacother 2004;38:1692-701.
APA Altıntaş Aykan D, ERGÜN Y (2019). Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. , 646 - 652. 10.5455/annalsmedres.2018.12.279
Chicago Altıntaş Aykan Duygun,ERGÜN Yusuf Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. (2019): 646 - 652. 10.5455/annalsmedres.2018.12.279
MLA Altıntaş Aykan Duygun,ERGÜN Yusuf Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. , 2019, ss.646 - 652. 10.5455/annalsmedres.2018.12.279
AMA Altıntaş Aykan D,ERGÜN Y Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. . 2019; 646 - 652. 10.5455/annalsmedres.2018.12.279
Vancouver Altıntaş Aykan D,ERGÜN Y Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. . 2019; 646 - 652. 10.5455/annalsmedres.2018.12.279
IEEE Altıntaş Aykan D,ERGÜN Y "Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?." , ss.646 - 652, 2019. 10.5455/annalsmedres.2018.12.279
ISNAD Altıntaş Aykan, Duygun - ERGÜN, Yusuf. "Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?". (2019), 646-652. https://doi.org/10.5455/annalsmedres.2018.12.279
APA Altıntaş Aykan D, ERGÜN Y (2019). Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. Annals of Medical Research, 26(4), 646 - 652. 10.5455/annalsmedres.2018.12.279
Chicago Altıntaş Aykan Duygun,ERGÜN Yusuf Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. Annals of Medical Research 26, no.4 (2019): 646 - 652. 10.5455/annalsmedres.2018.12.279
MLA Altıntaş Aykan Duygun,ERGÜN Yusuf Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. Annals of Medical Research, vol.26, no.4, 2019, ss.646 - 652. 10.5455/annalsmedres.2018.12.279
AMA Altıntaş Aykan D,ERGÜN Y Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. Annals of Medical Research. 2019; 26(4): 646 - 652. 10.5455/annalsmedres.2018.12.279
Vancouver Altıntaş Aykan D,ERGÜN Y Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?. Annals of Medical Research. 2019; 26(4): 646 - 652. 10.5455/annalsmedres.2018.12.279
IEEE Altıntaş Aykan D,ERGÜN Y "Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?." Annals of Medical Research, 26, ss.646 - 652, 2019. 10.5455/annalsmedres.2018.12.279
ISNAD Altıntaş Aykan, Duygun - ERGÜN, Yusuf. "Maternal antibiotic exposure and fetal outcomes: Is there evidence for teratogenicity?". Annals of Medical Research 26/4 (2019), 646-652. https://doi.org/10.5455/annalsmedres.2018.12.279